| Literature DB >> 32316537 |
Darío Manzanares1,2, Valentín Ceña1,2.
Abstract
Nanoparticles (NPs) and submicron particles are increasingly used as carriers for delivering therapeutic compounds to cells. Their entry into the cell represents the initial step in this delivery process, being most of the nanoparticles taken up by endocytosis, although other mechanisms can contribute to the uptake. To increase the delivery efficiency of therapeutic compounds by NPs and submicron particles is very relevant to understand the mechanisms involved in the uptake process. This review covers the proposed pathways involved in the cellular uptake of different NPs and submicron particles types as well as the role that some of the physicochemical nanoparticle characteristics play in the uptake pathway preferentially used by the nanoparticles to gain access and deliver their cargo inside the cell.Entities:
Keywords: caveolin; clathrin; endocytosis; macropinocytosis; nanoparticles
Year: 2020 PMID: 32316537 PMCID: PMC7238190 DOI: 10.3390/pharmaceutics12040371
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Main energy-dependent uptake pathways of the cell. Macropinocytosis forms macropinosomes that could finally join the early endosomes. Clathrin-mediated endocytosis (CME) and caveolin mediated endocytosis (CVME) are the main receptor-mediated endocytosis (RME) processes. On the other hand, other endocytic RME mechanisms as flotillin, ARF6, RhoA, or CDC42 mediated endocytosis are also present in the cell. The final fate of endosome vesicles is to fuse with lysosomes.
Figure 2Receptor mediated endocytosis. A specific interaction of a ligand on the surface of a nanoparticle (NP) (in blue) with a receptor (in green) triggers the formation of an invagination on the cell membrane which finally leads to the formation of an endosome thanks to the proteins implicated in each of the different pathways.
Figure 3Representation of the different kinds of NPs included in this review.
Main endocytosis pathways for every nanoparticle (NP) kind described in this review article, considering factors as size, charge, or shape.
| NP Type | Main Endocytic Pathway | Size/Length | Charge | Shape | Reference(s) | |
|---|---|---|---|---|---|---|
| Natural polymers | CS | CME | 15–250 nm | Positive | Ellipsoidal and spherical | [ |
| Albumin | CME | 140 nm | Positive | Spherical | [ | |
| CME | 150 nm | Negative | Spherical | [ | ||
| CVME | 120 nm | Negative | Spherical | [ | ||
| Alginate | CME | 50–120 nm | Negative | Spherical | [ | |
| CVME | 420 nm | Negative | Spherical | [ | ||
| Macropinocytosis | 730 nm | Negative | Spherical | [ | ||
| Synthetic polymers | Polystyrene | CME and passive diffusion | 40–150 nm | Negative | Not specified | [ |
| PLGA | CME | 80 nm | Positive | Not specified | [ | |
| Weak entrance CME and CVME independent | 80 nm | Negative | Not specified | [ | ||
| PEI | CME and CVME | 100–130 nm (25 kDa) | Positive | Branched | [ | |
| CME | 25 kDa | Positive | Linear | [ | ||
| Dendrimers | PAMAM -NH2 | CME | G4 (5–150 nm) | Positive | Branched | [ |
| CME and CVME | G2 | Positive | Branched | [ | ||
| PAMAM -OH | CVME | G4 | Negative | Branched | [ | |
| PAMAM -COOH | CVME | G3.5 | Negative | Branched | [ | |
| CME | G1.5 | Negative | Branched | [ | ||
| PAMAM | CME and CVME independent | G4 | Neutral | Branched | [ | |
| Lipids | CME and macropinocytosis | 100–150 nm | Positive | Spherical | [ | |
| Liposomes | CME and macropinocytosis | 100 nm | Negative | Spherical | [ | |
| CME and CVME | 100 nm | Neutral | Spherical | [ | ||
| SLNs | CME | 110–160 nm | Positive | Not specified | [ | |
| CME, CVME and macropinocytosis | 85–90 nm | Negative | Not specified | [ | ||
| Carbon based | SWCNTs | Macropinocytosis and non-specific interactions | 195–630 nm | Negative | Cylindrical | [ |
| Passive diffusion | 50 nm | Negative | Cylindrical | [ | ||
| MWCNTs | CME and CVME | 10 µm | Negative | Cylindrical | [ | |
| Fullerenes | Passive diffusion | 1 nm (55 nm aggregates) | Negative | Icosaedral | [ | |
| Carbon oxide NPs | Unspecific interactions | 38 nm (225 nm aggregates) | Negative | Irregular | [ | |
| QDs | CVME and CME | 10–50 nm | Negative | Ellipsoidal | [ | |
| Metallic | IONPS | CVME | 15–50 nm | Negative | Not specified | [ |
| CME (Macropinocytosis in absence of FBS) | 15–45 nm | Negative | Spherical | [ | ||
| AuNPs | Macropinocytosis | 80 nm | Negative | Spherical | [ | |
| CME and CVME (Macropinocytosis in absence of FBS) | 15 nm | Negative | Star | [ | ||
| CME (CME and CVME independent way in absence of FBS) | 33 × 10 nm | Negative | Rod | [ | ||
| MSNPs | CME and CVME independent | 300 nm | Negative | Not specified | [ | |
| RME, macropinocytosis and simple diffusion | 50–300 nm | Negative | Not specified | [ | ||
| CVME | 200 nm | Negative | Rod | [ | ||
| CME | 90–190 nm | Negative | Spherical | [ | ||
| CDNPs | CME | 40–140 nm | Positive | Not specified | [ | |
| Micelles | Gemini surfactants (14-2-14, 16-2-16, 12-2-12, 12-5-12, 12-10-12) | Direct translocation | 3 µm (1–6 µm) | Positive | Spherical | [ |
| Gemini surfactants with HL (14-2-14, 16-2-16, 12-2-12, 12-5-12, 12-10-12) | Macropinocytosis | 3 µm (1–6 µm) | Negative | Spherical | [ | |
| Gemini surfactant (14Ser)2N5/ DNA/HL | Energy independent processes | 200 nm | Negative | Spherical | [ | |
| Gemini surfactant (16Ser)2N5/DNA | CME | 550 nm | Positive | Spherical | [ | |
| Gemini surfactant 14-2-14/DNA (with or without HL) | Macropinocytosis and CVME | 555–800 nm | Positive | Spherical | [ | |
| Pluronic | CVME | 2–5 nm | Neutral | Unimers | [ | |
| CME | 15-50 nm | Neutral | Cross-linked micelles (spherical) | [ | ||
| PEG-PCL | CME and CVME | 20–30 nm | Positive | Spherical | [ | |
| CME and CVME | 20–30 nm | Positive | Spherical | [ | ||
| mPEG-PLGA | CME and CVME | 30 nm | Not specified | Spherical | [ | |
| PEG-PLA | CVME | 45 nm | Negative | Spherical | [ | |
| PEG-D-tocopheryl succinate | CVME | 15 nm | Neutral | Spherical | [ | |
| HA | CME and macropinocytosis | 130 nm | Neutral | Spherical | [ | |
Abbreviations: NP = nanoparticle, CS = chitosan, PLGA = poly(lactic-co-glycolic) acid, PEI = polyethylenimine, PAMAM = polyamidoamine, SLNs = solid lipid NPs, SWCNTs = single-walled carbon NPs, MWCNTs = multi-walled carbon NPs, QDs = quantum dots, IONPs = iron oxide NPs, AuNPs = gold NPs, FBS = fetal bovine serum, MSNPs = mesoporous silica NPs, CDNPs = β-cyclodextrin-based nanoparticles, HL = helper lipid, CME = clathrin-mediated endocytosis, CVME = caveolin-mediated endocytosis, PEG-PCL = PEG-co-poly(ε-caprolactone), PEG-DSPE = PEG-(distearoyl-snglycero-3-phosphoethanolaminen), mPEG-PLGA = methoxyPEG-PLGA, PEG-PLA = PEG-polylactic acid, HA = hyaluronic acid.